PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Parecoxib In Post Surgery (Hemicolectomy) Pain
Phase 3
Terminated
- Conditions
- Colectomy
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2009-08-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00139607
- Locations
- ๐ฎ๐น
Pfizer Investigational Site, Siena, Italy
12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation
Phase 2
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT00139750
- Locations
- ๐ฏ๐ต
Pfizer Investigational Site, Ohita, Japan
US Inhaled Insulin Therapeutic Choice Questionnaire Study
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2007-03-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 740
- Registration Number
- NCT00139763
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
Parecoxib in Renal Colic
Phase 3
Terminated
- Conditions
- Colic
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-05-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT00139646
- Locations
- ๐ฎ๐น
Pfizer Investigational Site, Siena, Italy
Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 138
- Registration Number
- NCT00139711
- Locations
- ๐ฎ๐น
Pfizer Investigational Site, Varses, Italy
Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).
Phase 4
Completed
- Conditions
- Colorectal Neoplasms
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-03-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 137
- Registration Number
- NCT00140036
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, Fleurimont, Quebec, Canada
A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol
Phase 3
Completed
- Conditions
- Hyperlipidemia
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3800
- Registration Number
- NCT00138762
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Warminster, Wiltshire, United Kingdom
An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.
Phase 2
Completed
- Conditions
- Urinary Incontinence, Stress
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2011-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 402
- Registration Number
- NCT00138749
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, Pointe-Claire, Quebec, Canada
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD
Phase 3
Terminated
- Conditions
- Diabetes MellitusChronic Obstructive Pulmonary Disease
- Interventions
- Drug: Subcutaneous Insulin
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 105
- Registration Number
- NCT00138671
- Locations
- ๐ฉ๐ช
Pfizer Investigational Site, Neuss, Germany
Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate
Phase 3
Completed
- Conditions
- Hyperlipidemia
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2007-10-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 128
- Registration Number
- NCT00139061
- Locations
- ๐ซ๐ท
Pfizer Investigational Site, Tierce, France
ยฉ Copyright 2025. All Rights Reserved by MedPath